From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer

Abdulrahman Alhajahjeh,Raad Al-Faouri,Hisham F. Bahmad,Taima’ Bader,Ryan W. Dobbs,Ahmed A. Abdulelah,Wassim Abou-Kheir,Elai Davicioni,David I. Lee,Mohammed Shahait,Taima' Bader

DOI: https://doi.org/10.3390/cancers16081538

2024-04-19

Cancers

Abstract:Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells. We discuss the potential pathways involving cAMP, ERK, AMPK, mTOR, and P27. Furthermore, we underscore the imperative for additional research to elucidate the impact of GLP-1-RA treatment on PCa progression, patient outcomes, and potential interactions with existing therapies. Translational studies and clinical trials are crucial for a comprehensive understanding of the role of GLP-1-RA in PCa management.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the potential role and mechanism of glucagon - like peptide - 1 receptor agonists (GLP - 1 - RA) in prostate cancer (PCa). Specifically, the paper focuses on the following aspects:

1. **The influence of GLP - 1 - RA on prostate cancer cells**: Research whether GLP - 1 - RA can inhibit the proliferation of prostate cancer cells, promote apoptosis and affect angiogenesis.

2. **The mechanism of action of GLP - 1 - RA**: Explore which signaling pathways (such as cAMP, ERK, AMPK, mTOR, P27, etc.) GLP - 1 - RA uses to affect the behavior of prostate cancer cells.

3. **Clinical evidence**: Analyze the existing clinical data, evaluate the impact of GLP - 1 - RA treatment on the incidence and progression of prostate cancer, and its interaction with existing therapies.

4. **Future research directions**: Propose translational research and clinical trials that need to be carried out in the future to fully understand the role of GLP - 1 - RA in prostate cancer management.

### Summary of main problems

- **The influence of GLP - 1 - RA on prostate cancer cells**: Can GLP - 1 - RA inhibit the proliferation of prostate cancer cells, promote apoptosis, and affect angiogenesis?
- **The mechanism of action of GLP - 1 - RA**: Which signaling pathways (such as cAMP, ERK, AMPK, mTOR, P27, etc.) does GLP - 1 - RA use to affect prostate cancer cells?
- **Clinical evidence**: Does the existing clinical data support the application of GLP - 1 - RA in the treatment of prostate cancer?
- **Future research directions**: What translational research and clinical trials need to be carried out in the future to further verify the role of GLP - 1 - RA in prostate cancer management?

Through these studies, the paper aims to provide a scientific basis for the potential application of GLP - 1 - RA in the treatment of prostate cancer and guide future clinical research.